Federal Agency · Defense Health Agency Contracting Activity - DHACA
DoW Parkinson’s, Early Investigator Research Award
Last updated: September 6, 2026
Posted June 18, 2026
Funding
Funding amount not specified
Closes
November 6, 2026
NAICS
541715
Summary: The fiscal year 2026 (FY26) Parkinson’s Research Program (PRP) Early Investigator Research Award (EIRA) supports Parkinson’s disease (PD) research for investigators in the early stages of their careers. The FY26 EIRA offers two funding levels, which align to the research career stage of the Principal Investigator (PI). Funding Level 1 (for fellows) requires the investigator to receive guidance from a designated Mentor, whereas Funding Level 2 (for early-career independent investigators) does not. Proposed research must address at least one of the four FY26 PRP Focus Areas . Distinctive Features: · The Early Investigator is considered the PI of the application and must exhibit strong potential for and commitment to pursuing a career as an investigator at the forefront of PD research; however, the PI is not required to have previous PD research experience. · Funding Level 1: Applications must include at least one Mentor appropriate to the proposed research project who has experience in PD research and mentoring, as demonstrated by a record of active funding, recent publications, and successful mentorship. The selected Mentor(s) should also demonstrate a clear commitment to the development of the PI toward independence as a PD researcher. Preliminary data are encouraged but not required . · Funding Level 2: Mentor not required. Preliminary data are required . · Clinical trials are not allowed.
Eligibility
- Funded by DoD-generic
Award details
Applications close on November 6, 2026 (60 days remaining).
Categories
Not categorized
Sign up at GrantRegister to see if this grant matches your organization.
Match my organization →View application on Grants.gov →·Source: Grants.gov·Last seen Sep 6, 2026
Similar grants
- Applied Drug Policy Research ExperiencesOffice of National Drug Control Policy · closes September 6, 2026
- Building Lasting U.S.-Chad Partnerships to Promote American ExcellenceU.S. Mission to Chad · closes September 6, 2026
- Alcohol Health Services Research (R01 Clinical Trial Optional)National Institutes of Health · closes September 7, 2026
- Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)National Institutes of Health · closes September 7, 2026
- Social disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional)National Institutes of Health · closes September 7, 2026
- Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)National Institutes of Health · closes September 7, 2026
- Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)National Institutes of Health · closes September 7, 2026
- National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional)National Institutes of Health · closes September 7, 2026
